Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.5K
Immunoglobulin-like Cell Adhesion Molecules01:31

Immunoglobulin-like Cell Adhesion Molecules

3.9K
Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
3.9K
The Tumor Microenvironment02:17

The Tumor Microenvironment

7.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.5K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

9.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.6K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

9.9K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
9.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.5K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is there a role for measuring coronary artery calcium progression in 2026?

American journal of preventive cardiology·2026
Same author

Finerenone Prescriptions in the United States (2021-2024) by Physician Specialty: Analysis of Use and Potential in the Cardiovascular-Kidney-Metabolic Space.

Journal of the American Heart Association·2026
Same author

Discovery of R-185 as a Potent and Orally Efficacious GPR52 Agonist with Potential for Treating Schizophrenia and Related Neuropsychiatric Disorders.

Journal of medicinal chemistry·2026
Same author

The Prognostic Value of Serum Interleukin-6 Concentrations for 9 Cardiovascular and Mortality Outcomes: The Cross Cohort Collaboration (CCC).

Journal of the American College of Cardiology·2026
Same author

US Trends in Prescribing Nonstatin Lipid-Lowering Therapy, 2019-2024.

JAMA cardiology·2026
Same author

KMT2A-rearranged B-lymphoblastic lymphomas are skewed towards a more mature developmental stage.

Leukemia·2026

Related Experiment Video

Updated: Dec 10, 2025

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.3K

Tenascin-C Function in Glioma: Immunomodulation and Beyond.

Fatih Yalcin1,2, Omar Dzaye1,2, Shuli Xia3,4

  • 1Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Advances in Experimental Medicine and Biology
|August 27, 2020
PubMed
Summary

Tenascin-C (TNC) is a protein involved in inflammation and cancer, particularly glioma. Understanding its immune interactions offers new therapeutic strategies for brain tumors.

Keywords:
AdhesionAngiogenesisBrainCancer stem cellsExtracellular matrixGliomaImmunomodulationInflammationIntegrinProliferationT cellsTenascin-CToll-like receptorTumor microenvironmentTumor-associated microglia/macrophages

More Related Videos

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma
09:06

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma

Published on: November 11, 2021

2.8K
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

16.3K

Related Experiment Videos

Last Updated: Dec 10, 2025

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.3K
Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma
09:06

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma

Published on: November 11, 2021

2.8K
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

16.3K

Area of Science:

  • Biochemistry
  • Immunology
  • Oncology

Background:

  • Tenascin-C (TNC) is an extracellular matrix glycoprotein crucial during development but typically absent in adult tissues.
  • TNC is re-expressed during pathological conditions like inflammation and cancer, correlating with disease progression and poor prognosis.
  • TNC influences cell behavior, including adhesion, migration, proliferation, and angiogenesis, by interacting with integrins and other molecules.

Purpose of the Study:

  • To elucidate the multifaceted roles of Tenascin-C (TNC) in regulating innate and adaptive immunity within the context of tumorigenesis and tumor progression.
  • To explore the impact of TNC on immune cells, specifically microglia, macrophages, and T cells, in glioma.
  • To identify potential therapeutic strategies targeting TNC for brain tumors and other malignancies.

Main Methods:

  • Review of existing literature on Tenascin-C (TNC) function, its interactions with immune cells, and its role in glioma.
  • Analysis of TNC's mechanisms of action, including its activation of toll-like receptor 4 (TLR4) and influence on macrophage polarization.
  • Examination of TNC's clinical significance as a biomarker and therapeutic target in glioma.

Main Results:

  • TNC acts as an endogenous activator of TLR4, promoting pro-inflammatory responses in microglia and macrophages and driving M1 polarization.
  • TNC exhibits immunosuppressive effects on T cells.
  • In glioma, TNC produced by tumor and stromal cells promotes invasion and angiogenesis and alters tumor-associated microglia/macrophage function, correlating with poor prognosis.

Conclusions:

  • Tenascin-C (TNC) plays a dual role in immunity, activating innate immunity while suppressing adaptive immunity, with significant implications in glioma.
  • TNC's impact on the tumor microenvironment, particularly immune cells, highlights its importance in cancer progression.
  • Targeting TNC and understanding its immune-modulating functions present promising avenues for novel cancer therapies, especially for brain tumors.